08:09 AM EDT, 10/07/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) said Tuesday that it has relaunched Orgovyx (relugolix) in Canada.

The medication is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by Health Canada for treating advanced prostate cancer and is publicly listed in most provinces.

Last year, Knight and Sumitomo Pharma America (SMPA) sealed exclusive agreements to commercialize Myfembree (relugolix/estradiol/norethindrone acetate), Orgovyx (relugolix) and vibegron in Canada, and an asset purchase agreement for Knight to acquire certain mature products.

"Orgovyx offers health care professionals a convenient oral alternative to rapidly suppress testosterone production for patients with prostate cancer," said chief executive Samira Sakhia.